Placebo capsules + Bardoxolone methyl capsules
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Conditions
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Trial Timeline
Oct 4, 2016 → May 7, 2020
NCT ID
NCT02657356About Placebo capsules + Bardoxolone methyl capsules
Placebo capsules + Bardoxolone methyl capsules is a phase 3 stage product being developed by Biogen for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT02657356. Target conditions include Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
What happened to similar drugs?
1 of 2 similar drugs in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02657356 | Phase 3 | Terminated |
Competing Products
2 competing products in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sildenafil | Pfizer | Approved | 43 |
| Belimumab | ICON plc. | Phase 3 | 44 |